X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Orchid Chemicals with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA LTD vs CADILA HEALTHCARE - Comparison Results

ORCHID PHARMA LTD    Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA LTD CADILA HEALTHCARE ORCHID PHARMA LTD/
CADILA HEALTHCARE
 
P/E (TTM) x -0.1 18.1 - View Chart
P/BV x 0.1 4.1 2.7% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 ORCHID PHARMA LTD   CADILA HEALTHCARE
EQUITY SHARE DATA
    ORCHID PHARMA LTD
Sep-13
CADILA HEALTHCARE
Mar-18
ORCHID PHARMA LTD/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs194558 34.8%   
Low Rs35362 9.7%   
Sales per share (Unadj.) Rs276.5116.3 237.7%  
Earnings per share (Unadj.) Rs-79.217.9 -443.3%  
Cash flow per share (Unadj.) Rs-43.523.1 -187.8%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs53.985.4 63.1%  
Shares outstanding (eoy) m70.451,023.74 6.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.44.0 10.5%   
Avg P/E ratio x-1.425.7 -5.6%  
P/CF ratio (eoy) x-2.619.9 -13.3%  
Price / Book Value ratio x2.15.4 39.4%  
Dividend payout %019.6 0.0%   
Avg Mkt Cap Rs m8,067470,664 1.7%   
No. of employees `0002.811.8 23.7%   
Total wages/salary Rs m2,52718,545 13.6%   
Avg. sales/employee Rs Th6,956.110,072.7 69.1%   
Avg. wages/employee Rs Th902.51,569.1 57.5%   
Avg. net profit/employee Rs Th-1,993.01,547.7 -128.8%   
INCOME DATA
Net Sales Rs m19,477119,049 16.4%  
Other income Rs m4071,132 36.0%   
Total revenues Rs m19,884120,181 16.5%   
Gross profit Rs m1,10328,475 3.9%  
Depreciation Rs m2,5195,388 46.8%   
Interest Rs m5,227911 573.7%   
Profit before tax Rs m-6,23623,308 -26.8%   
Minority Interest Rs m20628 3.1%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m5110-   
Tax Rs m-1255,644 -2.2%   
Profit after tax Rs m-5,58018,292 -30.5%  
Gross profit margin %5.723.9 23.7%  
Effective tax rate %2.024.2 8.3%   
Net profit margin %-28.715.4 -186.5%  
BALANCE SHEET DATA
Current assets Rs m11,01482,005 13.4%   
Current liabilities Rs m32,06060,720 52.8%   
Net working cap to sales %-108.117.9 -604.4%  
Current ratio x0.31.4 25.4%  
Inventory Days Days9573 129.7%  
Debtors Days Days3498 34.1%  
Net fixed assets Rs m29,44083,703 35.2%   
Share capital Rs m7051,024 68.8%   
"Free" reserves Rs m2,04386,421 2.4%   
Net worth Rs m3,80087,445 4.3%   
Long term debt Rs m9,01825,551 35.3%   
Total assets Rs m46,510180,653 25.7%  
Interest coverage x-0.226.6 -0.7%   
Debt to equity ratio x2.40.3 812.2%  
Sales to assets ratio x0.40.7 63.5%   
Return on assets %-0.810.6 -7.2%  
Return on equity %-146.920.9 -702.0%  
Return on capital %-3.722.0 -17.0%  
Exports to sales %37.90-   
Imports to sales %22.60-   
Exports (fob) Rs m7,378NA-   
Imports (cif) Rs m4,406NA-   
Fx inflow Rs m7,51342,683 17.6%   
Fx outflow Rs m5,64911,242 50.2%   
Net fx Rs m1,86531,441 5.9%   
CASH FLOW
From Operations Rs m1,6829,193 18.3%  
From Investments Rs m-9,860-9,737 101.3%  
From Financial Activity Rs m6,644515 1,290.1%  
Net Cashflow Rs m-1,535-29 5,293.1%  

Share Holding

Indian Promoters % 32.3 74.8 43.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.6 8.3 55.4%  
FIIs % 3.3 5.9 55.9%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 11.0 502.7%  
Shareholders   84,811 44,069 192.5%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA LTD With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  FDC LTD.  ASTRAZENECA PHARMA  STRIDES PHARMA SCIENCE  

Compare ORCHID PHARMA LTD With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 150 Points Higher; Banking Stocks Witness Buying(Closing)

Indian share markets continued their momentum and ended the day on a positive note. Gains were largely seen in the banking sector, consumer durables sector and realty sector.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA LTD SHARE PRICE


Dec 13, 2018 (Close)

TRACK ORCHID PHARMA LTD

  • Track your investment in ORCHID PHARMA LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ORCHID PHARMA LTD

ORCHID PHARMA LTD 5-YR ANALYSIS

COMPARE ORCHID PHARMA LTD WITH

MARKET STATS